CLINICAL TRIALS PROFILE FOR AVELOX
✉ Email this page to a colleague
All Clinical Trials for Avelox
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00082173 ↗ | Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis | Completed | Johns Hopkins University | Phase 2 | 2004-10-01 | Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB. |
| NCT00158093 ↗ | A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo | Completed | Mylan Bertek Pharmaceuticals | Phase 1 | 2003-06-01 | Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7. |
| NCT00280514 ↗ | Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration | Completed | Medical University of Vienna | Phase 4 | 2006-01-01 | Penetration of cefpirome and moxifloaxacin into abscess fluid of humans will be tested. Patients with an abscess scheduled for drainage will receive study drugs (single or multiple dose), pus samples and plasma samples will be collected and analyzed by High pressure liquid chromatography (HPLC). Pharmacokinetics of the study drugs in pus and plasma will be determined using a pharmacokinetic model. |
| NCT00492024 ↗ | BAY12-8039: 5 Days for Sinusitis vs Placebo | Completed | Bayer | Phase 3 | 2005-01-01 | The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of acute bacterial sinusitis, therefore in this study Avelox is considered an investigational drug. In this study Avelox will be compared to placebo. |
| NCT00537563 ↗ | AMS VS MOXI Ketek vs Avelox in AMS | Completed | Sanofi | Phase 3 | 2002-12-01 | Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS. |
| NCT00665327 ↗ | Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia | Completed | Bayer | Phase 4 | 2002-11-01 | This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged ≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs. |
| NCT00668304 ↗ | Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox | Completed | Bayer | Phase 4 | 2004-06-01 | This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Avelox
Condition Name
Clinical Trial Locations for Avelox
Trials by Country
Clinical Trial Progress for Avelox
Clinical Trial Phase
Clinical Trial Sponsors for Avelox
Sponsor Name
